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Abstract
Background: Surveillance data on the proportion of incident TB cases with MDR was limited and there is no systematic
study of MDR-TB in China to date. Our aim was to estimate MDR-TB disease burden in 2012 and change trends during
2003–2012 using spatio-temporal systematic analysis.
Methods: We systematically searched Chinese and English databases for primary articles and reviews that
contain MDR-TB survey data about China during the period of 2003–2012. We estimated the proportion of
incident TB cases with MDR in cities which had no data to report in 2012 by Kriging spatial interpolation
analysis. The primary outcomes were the proportion of incident TB cases with MDR at 2012 and the change
trend during 2003–2012.
Results: Total 487 articles met the screening criteria, including 450 in Chinese and 37 in English, and have been
used in analysis. The proportion of incident TB cases with MDR among all cases in 2012 showed clear geographic
differences. From 2003 to 2012, the proportion of incident TB cases with MDR in all, new and previously treated TB
cases were higher during 2006–2009 and significantly lower during 2010–2012 in comparison with the period during
2003–2005 (P < 0.0167). The estimated median proportion of incident TB cases with MDR among all cases, as well as in
new and previously treated cases in 2012 was 12.8% (IQR 9.8–17.3%), 5.4% (4.5–7.3%) and 28.5% (20.5–30.9%)
respectively, which led to an estimate of 121,600 (IQR93,000–164,350) MDR-TB cases in China.
Conclusions: This estimate of MDR-TB burden is considerably higher than data reported by the Chinese fifth
national tuberculosis epidemiological sampling survey in 2010 but close to the WHO report, which implies that
detailed investigations of MDR-TB burden in China is needed. This research provides data to guide public
health decisions at various scales; methods described here can be extended to estimate of the other chronic
diseases as well.
Keywords: Multidrug-resistant tuberculosis (MDR-TB), Disease burden, Spatio-temporal analysis, Systems
analysis, Kriging interpolation
Background
Based on data emerging from drug resistance surveys
and continuous surveillance among notified TB cases,
the Global Tuberculosis Report suggested that, globally,
an estimated 3.3% of new TB cases and 20% of previously
treated cases were infected with Multidrug-resistant tu-
berculosis (MDR-TB) in 2014 [1]. An estimated 480,000
people who developed MDR-TB and 190,000 people died
of MDR-TB; with more than half of them (54%) occurring
in India, China and the Russian Federation. The number
of MDR-TB patients in China followed India and ranked
second in the world. The report estimated that 5.7%
(4.5–7.0%) incident TB cases with MDR among new
cases and 26%(22–30%) among previously treated cases
in China [1].
The Chinese government has been involved in exten-
sive efforts to prevent and control MDR-TB. In 2006,
China initiated the fifth round of the Global Fund
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tuberculosis (TB) project in Hebei, Jilin, Jiangsu,
Yunnan, Guangxi, Sichuan, and Shaanxi province to
target at MDR-TB specifically [2]. During 2007–2008, the
Ministry of Health organized a nationwide baseline survey
for TB drug resistance [3], and the results indicated that
the prevalence of MDR-TB was 8.32% (95%CI, 7.13 to
9.70) with 120,000 new MDR-TB cases occurring every
year, which estimated about 110,000(95%CI, 97,000 to
130,000) new MDR-TB cases occurring every year, which
accounted for about a quarter of the globally total number
of new MDR-TB cases in a year. The fifth national tuber-
culosis epidemiological sampling survey in 2010 suggested
that the total proportion of incident TB cases with MDR
was 6.8%, with 5.4% of new cases and 15.4% of previously
treated cases [4].
MDR-TB patients need at least 24 months of treatment
in general and the severe cases may need 36 months of
treatment,however, the cure rate is only around 50 to 60%
[5–8],which makes the economic burden of MDR-TB as
high as 10–100 times comparing with non MDR-TB cases
[9, 10]. MDR-TB takes longer to treat with second-line
drugs, which are more expensive and have more side-
effects [11].
Therefore, to control the proportion of incident TB
cases with MDR is a top public health priority in
China [12].
However, very few cases were tested for TB sensitivity
at present time in China, for example, only 280 cases
completed TB sensitivity test in the fifth national tuber-
culosis epidemiological sampling survey in 2010 [4], in-
dicating the survey may not represent whole MDR-TB
epidemic. Another important nationwide baseline survey
for TB drug resistance in 2007–2008 has lasted 7 years
[3], so reliable estimate of the proportion of incident TB
cases with MDR is essential to prevent and control
MDR-TB. Spatio-temporal analysis refers to the spatial
distribution and changing trends with time of the pro-
portion of incident TB cases with MDR [13]. In this
study, we aimed to update the estimate of MDR-TB bur-
den in China by a spatio-temporal systematic analysis
across 2003–2012.
Methods
MDR-TB is defined as TB disease caused by organisms
that are resistant to isoniazid and rifampicin, two major
first-line anti-TB drugs. We divided MDR-TB case into
three groups: all cases, new cases, and previously treated
cases. The new case is defined as a patient who has re-
ceived no or less than 1 month of anti-tuberculosis treat-
ment, the previously treated case is defined as a patient
who has been treated for 1 month or longer using anti-
tuberculosis medication, and the all case was defined as
an MDR-TB case regardless of the treatment history [5].
The proportion of incident TB cases with MDR
equaled the number of MDR divided by the total number
of culture-positive mycobacterium tuberculosis (MTB),
multiplied by 100%.We have calculated it for three groups
(all, new, and previously treated cases) based on the arti-
cles reports respectively.
Data source and study design
We systematically searched Chinese CNKI, WANGFANG
DATA, VIP databases and English PubMed, and Web of
Science databases for primary articles and reviews. The
search keywords were ‘multidrug-resistant tuberculosis’ or
‘drug-resistant tuberculosis’ (Appendix 1). We contacted
authors for additional information if the information in
the articles was not clearly presented.
MDR-TB burden was analyzed and evaluated by five-
steps. First, we acquired and screened the proportion of
incident TB cases with MDR at provincial and city level
respectively through articles retrieval. Second, we classi-
fied the proportion of incident TB cases with MDR into
three groups (all cases, new cases and the previously
treated cases) at the provincial and city level. Third, we
estimated the proportion of incident TB cases with
MDR based on provincial level. If this data was absent in
certain regions in 2012, we used data from 2011 or 2010
considering of 2–3 years treatment duration for MDR-TB
and the proportion was unlikely to change significantly
within 2–3 years. Fourth, we estimated the proportion in
cities during 2012 using the Kriging spatial interpolation
analysis method. The primary outcomes were the propor-
tion of incident TB cases with MDR in 2012 and the
change trend during 2003–2012.
Selection and exclusion criteria
Below we describe the selection criteria for the study.
The study area included China’s provinces and cities; we
considered studies from Jan. 1, 2003 to Dec. 31, 2012.
Second, articles was required to include survey time,
area, the number of TB cases which tested for TB resist-
ance, MDR-TB case numbers, resistance test methods
and standards of classification. When several surveys
were all conducted in same area, we kept only the most
informative one.
We excluded the articles which contained duplicate in-
formation, or the sample size less than 50. We also ex-
cluded the articles describing tests that were carried out
for specific populations, such as the elderly, children,
prisoners and migrants; the articles describing MDR-TB
patient co-infected with other diseases, such as HIV, and
diabetes also were also excluded.
Data extracted from each article included: survey area,
time of the drug resistance test, number of TB cases
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which received drug susceptibility testing for isoniazid
and rifampicin, the number of MDR-TB cases. MDR-TB
data was further classified into all cases, new cases and
the previously treated case respectively.
Two investigators were independently responsible for
data selection, exclusion, and extraction; if there was dis-
agreement, a discussion to agreement would follow; if
this failed, a third person was invited to make the
judgment.
Statistical analysis
There were abundant dataset in the eastern and central
areas of China, so we estimated the proportion of incident
TB cases with MDR at city level (or scale) which had
not been report in 2012 by Kriging spatial interpolation
analysis in those areas. Kriging spatial interpolation
analysis is a classical geostatistical analysis method and
based on rules of space at correlation quantize between
the sample points, which we can calculate the propor-
tion of incident TB cases with MDR for no data area by
using the known sample points area [14–16], the cross
validation method can improve the accuracy of prediction.
There are scarce data available in the western area,
therefore, the spatial interpolation analysis was con-
ducted only in eastern and central area, and used the
provincial data in the western areas to estimate the
MDR-TB for nationwide.
Considering the stability of the proportion of incident
TB cases with MDR at a short period and the data is
rarely in same area in different year during 2003–2012,
so we classified the 10 years into three periods: 2003–
2005, 2006-2009and 2010–2012. There are two reasons
that the years 2005 and 2009 were chosen to define the
time periods: in 2002, the largest TB project worldwide
was launched by the Chinese government to reinvigorate
DOTS, and the government (national, provincial, and
rural counties) increased funding on TB control nation-
wide from 2003 [2, 17]; in 2005, China fulfilled its com-
mitment to the WHO to detecting 70% of all new
smear-positive cases and to successfully treat 85% of
these cases nationwide; On July. 13, 2009, the Ministry
of Health of China and the Bill & Melinda Gates Foun-
dation initiated a TB control project in Beijing [17].
Therefore, the years 2003, 2005 and 2009 indicate
meaningful time points for TB prevention and control
in China.
Change of the proportion of incident TB cases with
MDR in the three periods was examined separately using
the multiple chi-square tests using SPSS 22.0 (IBM). The
P-value has a new criterion in the multiple testing, our
article involves three pairs comparisons, so the criterion
was 0.05/3 = 0.167, when P < 0.167, we could get the
conclusion: the differences were significant.
Results
Total 487 articles met the screening criteria, with 450 in
Chinese and 37 in English (Fig. 1), among them, 288
were concerned new cases of MDR-TB, 297 reported
previously treated cases of MDR-TB and 436 involved all
cases of MDR-TB. Table 1 demonstrated the spatial dis-
tribution of articles in 31 provinces (see detail distribu-
tion of the number of TB and MDR-TB cases in 31
provinces in Appendix 2).
The median of estimated the proportion of incident
TB cases with MDR among all cases, new cases and previ-
ously treated cases in 2012 was 12.8% (IQR 9.8–17.3%),
5.4% (4.5–7.3%) and 28.5% (20.5–30.9%) respectively, the
number of TB cases was 0.95million in 2012 according to
the data from The Data-center of China Public Health Sci-
ence (Chinese Center for Disease Control and Prevention,
CDC), which led to an estimate of 121,600 (IQR93,000–
164,350) MDR-TB cases in China.
Figure 2a, b and c showed the proportion of incident
TB cases with MDR among all cases based on city level
(scale); among them, Fig. 2a showed the proportion of
incident TB cases with MDR obtained from articles re-
ports, the white blank areas refer to no data available;
487 articles
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98  repetitive articles for same research
56  little information research was 









exclude 8,212 duplicate articles  
after read title or abstracts:
exclude: 7799
821     inappropriate survey time
3,114  specific populations
726     co-infection 
3,138  other irrelevant research contents
Fig. 1 Flow chart of articles selection process in a systematic review
of the proportion of incident TB cases with MDR in China
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Fig. 2b presented the Kriging interpolation results. We
used Ordinary Kriging method and selected Exponential
Function as covariance model according the character-
istics of data and this model have a higher accuracy
after we tried other models, the case of 127(59%) areas
were used to estimate the overall numbers of cases.
We did the Kriging interpolation analysis only in east-
ern and central area (right side of red line in Fig. 2a)
since fewer dataset was available in western areas;
Fig. 2c showed that the proportion of incident TB
cases with MDR in nationwide, We used the provincial
data in Fig. 3 to make up the west blank area to esti-
mate the proportion of incident TB cases with MDR
in nationwide. Therefore, the proportion of incident
TB cases with MDR of western regions in Fig. 2c was
the provincial data from Fig. 3a, and the proportion of
incident TB cases with MDR of eastern and central
area in Fig. 2c was the Kriging interpolation result
from Fig. 2b. All spatial analysis was run in ArcGIS
10.2 (ESRI).
There was a clearly geographic difference of the
proportion of incident TB cases with MDR among
all cases in 2012 at provincial level (scale), with 4.2–
6.8% in 2 provinces, 6.8–15% in other 16 provinces
and 15–30% in 12 provinces (Fig. 3a). For the new
cases, the proportion was 3–5.4% in 15 provinces,
Table 1 the number of articles, the proportion of incident TB cases with MDR in 31 provinces
Area Articles number the proportion of incident TB cases with MDR (%)
all cases new cases previously treated cases all cases new cases previously treated cases
Anhui 23 8 8 15.04 4.5 35.61
Beijing 13 10 11 27.82 11.36 35.09
Chekiang 38 31 33 6.6 2.97 28.62
Chongqing 11 7 6 17.72 5.5 26.06
Fujian 15 13 12 9.77 4.63 19.69
Gansu 1 1 1 4.2 3.52 4.67
Guangdong 29 24 24 9.31 6.07 31.11
Guangxi 15 13 14 10.8 4.63 25.53
Guizhou 15 7 8 15.64 4.64 31.14
Hainan 1 1 1 13.49 5.1 29.91
Hebei 15 11 10 12.34 5.33 36.37
Heilongjiang 10 8 7 15.1 6.96 30.2
Henan 27 16 16 11.08 4.03 19.45
Hubei 18 14 17 24.27 4.47 22.37
Hunan 16 10 9 10.59 4.75 28.87
Jiangsu 30 22 22 16.92 5.5 29.3
Jiangxi 8 4 5 17.36 9.35 21.16
Jilin 13 5 6 18.59 2.94 13.71
Liaoning 11 10 9 17.41 6.52 29.36
Mongolia 4 2 2 29.03 7.38 39.71
Ningxia 7 4 4 9.56 7.69 28.4
Qinghai 0 0 0 nodata nodata nodata
Shaanxi 10 4 6 12.02 7.74 12.09
Shandong 22 12 12 12.99 5.73 32.64
Shanghai 21 11 13 7.1 3.38 20.28
Shanxi 8 5 5 12.68 4.43 43.02
Sichuan 18 9 10 8.47 4.62 28.22
Tianjin 7 6 6 13.64 9.09 22.73
Tibet 1 1 1 29.8 20.69 56.6
Xinjiang 20 12 12 8.63 7.21 11.82
Yunnan 9 7 7 10 12 14
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Fig. 2 Proportion of incident TB cases with MDR among all cases based
on city level. a Proportion of incident TB cases with MDR obtained from
articles reports, the white blank areas refer to no data available. b Kriging
interpolation result. We did the Kriging interpolation analysis only in
eastern and central area (right side of red line in Fig. 2a) since fewer data
was available in western areas. c Estimate the proportion of incident TB
cases with MDR in nationwide. We used the provincial date in Fig. 3 to
make up the west blank area to estimate the proportion of incident TB
cases with MDR in nationwide. Therefore, the proportion of incident TB
cases with MDR of western region in Fig. 2c was the provincial data from
Fig. 3a, and the proportion of incident TB cases with MDR of eastern and
central area in Fig. 2c was the Kriging interpolation result from Fig. 2b
Fig. 3 Estimate of the proportion of incident TB cases with MDR
based on provincial level. a Proportion of incident TB cases with
MDR among all cases. b Proportion of incident TB cases with MDR
among new cases. c Proportion of incident TB cases with MDR
among previously treated cases
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5.4–15% in 14 provinces and 15–21% in 1 province
(Fig. 3b). For the previously treated cases, 4.6–15.4%
in 5 provinces, 15.4–30% in 15 provinces and 30–57% in
10 provinces (Fig. 3c). It is unclear whether Tibet should
be included in the high burden region for new, previously
treated and all cases, as only one article report in Tibet
was found, which included 198 cases (see detail in Fig. 4,
Table 1).
During the period from 2003 to 2012, the proportion
of incident TB cases with MDR among all, new and
previously treated TB cases were all higher during
2006–2009 period and significantly lower during
2010–2012 period compared with 2003–2005 (P <
0.167), the proportion of incident TB cases with MDR
among previously treated cases was statistically signifi-
cant higher than that of new cases (P < 0.167). (Fig. 5,
Tables 2 and 3).
Complete dataset available only on 26 provinces out of
31 provinces around the country; and those datasets
were used to represent nationwide data. The spatial
distribution maps concerning the three groups in three
periods are presented in Figs. 6, 7, and 8.
Discussion and conclusions
The study results indicate that the proportion of inci-
dent TB cases with MDR in China is higher than other
international regions [1]. Factors contributing to the high
burden may include economic development, poor know-
ledge and side effects of TB treatment, poor quality DOTS,
lack of coordination of medical services, unsatisfactory
supervision of treatment and poor infection control
[18–21].
The estimates results in our study are higher than the
results in the fifth national tuberculosis epidemiological
sampling survey in 2010 [4] (12.8vs.6.8% in all cases, 5.4
vs.5.4% in new TB cases; 28.5 vs.15.4% in the previously
treated cases). The difference may be due to small sam-
pling size in the sample survey which only provided sus-
ceptible test for 280 TB cases, including 241 new cases
and 39 previously treated cases.
While, our estimated the proportion of incident TB
cases with MDR among new cases and previously
treated cases were close to the result from Global tu-
berculosis Report in 2013, 5.4% (4.5–7.3%) vs. 5.7%
(4.5–7.0%) in new TB cases; 28.5% (20.5–30.9%) vs.26%
(22–30%) in the previously treated cases. There was no
information concerning the proportion of incident TB
cases with MDR among all cases in Global tuberculosis
Report [1].
It is not a surprise that, our study reveals substantial
spatial differences in MDR-TB burden, consistent with
previous work [17]. We believe that the difference might
be linked to factors including local economy, education,
population density and mobility, ethnic minority pop-
ulations, and distribution of relevant diseases (such as










































Fig. 4 Proportion of incident TB cases with MDR in 31 provinces




























Fig. 5 Change trend of the proportion of incident TB cases with
MDR. The blue line showed the change trend among new cases in
three periods (2003–2005, 2006–2009, 2010–2012); The green line
showed the change trend among previously treated TB cases in
three periods; The red line showed the change trend among all
cases in three periods
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HIV/AIDS) based on geographic features. The high
burden provinces, Guangdong, Anhui, Jiangsu and
Hebei are good examples for relevant disease of AIDS
and density of population [22]. Guangdong has much
more complicated factors, such as large migrant popu-
lation [23].
Our study also indicates that the proportion of in-
cident TB cases with MDR among all TB cases had
a significantly higher during 2006–2009 periods and
then showed a decreased change during 2010–2012
compared with 2003–2005. The high rate of discov-
ery of TB cases stimulated by the TB project world-
wide and the Chinese government’s commitment to
detecting 70% of all new smear-positive cases and
successfully treat 85% of these cases nationwide contribute
to the increase of proportion during 2006–2009. This
increase is clearly resulted from the significant efforts
of the Chinese government to prevent and control TB
by launching a series of policies in past decades, and
not a real aggravation of MDR-TB burden in China
[17]. Following the implementation of policies con-
cerning TB prevention and control, a decline of the
proportion of incident TB cases with MDR would be
expected.
The proportion of incident TB cases with MDR
differed significantly among the three groups. The
new case group was an epidemiological index which
better reflect the effectiveness of TB control in re-
cent times. The previously treated case group was a
mixed index which is a reflection of both TB control
conditions and treatment efficacy in the past [24].
According our estimates, in the past 10 years, our
research results show that the proportion of incident
TB cases with MDR among new cases has only little
change, among previously treated case was shown to
be on the decline, but the proportion was extremely
higher than that of new cases. Therefore, we should
strengthen the drug management of MDR-TB patients,
and programmatic management of multidrug-resistant tu-
berculosis (MDR-TB), including standardized high quality
DST for patients, especially in high MDR-TB burden
regions [25].
Our study has several strengths. First, the search
strategy covered several databases and reported in two
languages which involved all provinces except for Qinghai;
in addition data for Hong Kong, Taiwan and Macao were
also unavailable, which reveals national MDR-TB burden.
Second, we propose a spatial systematic analysis by
using Kriging’s interpolation method which relies on
available data and predict the absence of data from
some cities in China. Such analysis would improve local
estimates as well as reduce uncertainty in regional and
national estimates. The national quantitative map pre-
sented here illustrates distribution of the proportion of
incident TB cases with MDR. This study is the first at-
tempt to quantify the national burden of MDR-TB in
China.
Although we used the strict search strategy and quality
control as soon as possible, there still maybe some po-
tential (major) source of bias in this article. First, the
DOTS strategy has a significant impact on the preva-
lence of MDR-TB, although China has realized 100%
complete coverage for DOTS strategy in 2007 [26], the
implement quality of DOTS strategy have differences in
Table 2 The number of articles, TB cases, MDR-TB cases, the proportion of incident TB cases with MDR in three periods




























92 61,363 7,846 12.89 9.21–
19.5
70 36,707 2,039 4.98 3.6–
8.64




181 129,058 18,807 14.02 11.23–
19.78
105 42,743 3,056 6.45 5.18–
10.58




167 132,929 16,725 12.74 9.6–
18.88
112 67,927 3,348 5.44 4.41–
7.72
124 23,304 5,783 26.51 19.6–
30.21
Table 3 The chi square test results of three periods in three groups
Date All cases New cases The previously treated cases
χ2 P value χ2 P value χ2 P value
2003–2005 compared with 2006–2009 110.242 0.000 83.841 0.000 19.252 0.000
2006–2009 compared with 2010–2012 221.338 0.000 237.354 0.000 121.712 0.000
2003–2005 compared with 2010–2012 1.586 0.208 19.121 0.000 24.652 0.000
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Fig. 6 Proportion of incident TB cases with MDR among all cases in
three periods. a Proportion of incident TB cases with MDR among all
cases in 2003–2005. b Proportion of incident TB cases with MDR
among all cases in 2006–2009. c Proportion of incident TB cases
with MDR among all cases in 2010–2012
Fig. 7 Proportion of incident TB cases with MDR among new cases
in three periods. a Proportion of incident TB cases with MDR among
new cases in 2003–2005. b Proportion of incident TB cases with
MDR among new cases in 2006–2009. c Proportion of incident TB
cases with MDR among new cases in 2010–2012
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different areas of China, especially in the poor eco-
nomic areas [27, 28]; Second, since eligible published
reports were not available for all of the 31 provinces/
municipalities, and not every study explored MDR-TB
in all three groups and three periods, therefore, we only
carried out change trend analysis in the data rich area
and spatial interpolation analysis in central and eastern
regions based on city scale; Third, due to the geograph-
ical, historical and cultural factors [29, 30], few articles
reports about the proportion of TB cases with MDR in
the Western areas of China, and the missing data of
western regions may affect the reliability of our study
result, therefore, we have to use provincial centers data
to estimate the entire province based on there was no
other data sources in these areas; Without long-term
nationwide surveillance data, the results obtained here
are so far the best data source to show the proportion
of incident TB cases with MDR among China in the
past 10 years.
These bias will hopefully encourage other investigators
to conduct further prospective studies, which include
the collection of high quality epidemiological and
microbiological surveillance data, the monitoring of
change trends of the proportion of incident TB cases
with MDR, and the detection of key groups of people
for further research and improved TB control in the
future [21].
Our research concerning the proportion of incident
TB cases with MDR provides an initial assessment of
the MDR-TB disease burden in China. Although re-
search is limited by the data source, it sheds light on
the prevalence and change trends of the proportion in
China. Detailed investigations of MDR-TB burden are
needed in China; this research provides a valuable tool
to guide public health decisions at various scales and




We applied the PRISMA guidelines for this systematic
review.
We systematically searched Chinese CNKI, WANG-
FANG DATA, VIP databases and English PubMed, and
Web of Science databases for primary articles and reviews.
The search keyword was ‘multidrug-resistant tuberculosis’
or ‘drug-resistant tuberculosis’. In fact, in the process of
search, we search all articles contains ‘multidrug-resistant
tuberculosis’ or ‘drug-resistant tuberculosis’ in the full text
to avoid miss articles. Articles were also searched manu-
ally and, if required and when it was feasible, authors were
contacted directly for unpublished data and additional
information.
Fig. 8 Proportion of incident TB cases with MDR among previously
treated cases in three periods. a Proportion of incident TB cases with
MDR among previously treated cases in 2003–2005. b Proportion of
incident TB cases with MDR among previously treated cases in
2006–2009. c Proportion of incident TB cases with MDR among
previously treated cases in 2010–2012
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Appendix 2
Appendix 3
List of references for the 487 studies
1. W Li, Z Ma, H Zhang, et al. Epidemic status of
MDR-TB of Kaifeng Prefecture in Henan[J]. Henan
J Prev Med, 2014, 25(2): 100–117.
2. W Li, X Li, Y Qu, et al. Investigation of multidrug-
resistance of smear-positive pulmonary tuberculosis
patients in Kaifeng city[J]. Chin. J of PH M., 2012,
28(4): 453–454.
3. J Su, G Liang, L Bao, et al. Analysis of culture and
drug-resistance of Mycobacterium tuberculosis in
Kunming [J]. Chin J Anti tuberculosis, 2012, 34(1):
32–35.
4. H Qiu, Z yan, T Yin. Monitoring Analysis of drug
-resistance TB patients in Kunming city [J]. Soft
Science of Heath, 2013, 27(1): 37–38.
5. Z Bi, H Ren, F Gao, et al. Analysis of drug resistance
trend on tuberculosis in Lang fang city [J]. Journal of
Clinical Pulmonary Medicine, 2012, 17(1): 75–77.
Table 4 Distribution of the number of cases
Areas date TB Case MDR-TB Case
all new previously treated all new previously treated
Anhui 2012 7,388 2,599 994 1,111 117 354
Beijing 2012 417 88 57 116 10 20
Chekiang 2012 11,216 9,439 1,887 740 280 540
Chongqing 2012 6,054 2,091 495 1,073 115 129
Fujian 2012 4,462 1,834 523 436 85 103
Gansu 2012 834 341 493 35 12 23
Guangdong 2012 7,033 4,758 1,305 655 289 406
Guangxi 2012 3,111 2,181 936 336 101 239
Guizhou 2012 2,481 474 334 388 22 104
Hainan 2012 126 1,196 341 17 61 102
Hebei 2012 3,971 2,927 866 490 156 315
Heilongjiang 2012 1,437 819 351 217 57 106
Henan 2012 3,502 1,813 622 388 73 121
Hubei 2012 5,938 2,060 2,097 1,441 92 469
Hunan 2012 1,180 547 239 125 26 69
Jilin 2012 1,818 102 890 338 3 122
Jiangsu 2012 9,058 5,531 1,536 1,533 304 450
Jiangxi 2012 1,365 813 189 237 76 40
Liaoning 2012 2,860 1,580 780 498 103 229
Mongolia 2012 2,556 610 1,040 742 45 413
Ningxia 2012 2,092 91 169 200 7 48
Qinghai 2012 nodata nodata nodata nodata nodata nodata
Shaanxi 2012 1,165 4,238 513 140 328 62
Shandong 2012 3,379 646 432 439 37 141
Shanghai 2012 13,934 9,702 1,277 990 328 259
Shanxi 2012 891 609 172 113 27 74
Sichuan 2012 2,656 2,012 489 225 93 138
Tianjin 2012 1,393 385 88 190 35 20
Tibet 2012 198 116 53 59 24 30
Xinjiang 2012 1,714 749 533 148 54 63
Yunnan 2012 694 152 36 113 7 5
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of clinical isolated mycobacterium tuberculosis [J].
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